These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Blood-brain barrier (BBB) pharmacoproteomics: reconstruction of in vivo brain distribution of 11 P-glycoprotein substrates based on the BBB transporter protein concentration, in vitro intrinsic transport activity, and unbound fraction in plasma and brain in mice. Uchida Y, Ohtsuki S, Kamiie J, Terasaki T. J Pharmacol Exp Ther; 2011 Nov; 339(2):579-88. PubMed ID: 21828264 [Abstract] [Full Text] [Related]
3. Pharmacoproteomics-based reconstruction of in vivo P-glycoprotein function at blood-brain barrier and brain distribution of substrate verapamil in pentylenetetrazole-kindled epilepsy, spontaneous epilepsy, and phenytoin treatment models. Uchida Y, Ohtsuki S, Terasaki T. Drug Metab Dispos; 2014 Oct; 42(10):1719-26. PubMed ID: 25061162 [Abstract] [Full Text] [Related]
5. Quantitative investigation of the brain-to-cerebrospinal fluid unbound drug concentration ratio under steady-state conditions in rats using a pharmacokinetic model and scaling factors for active efflux transporters. Kodaira H, Kusuhara H, Fuse E, Ushiki J, Sugiyama Y. Drug Metab Dispos; 2014 Jun; 42(6):983-9. PubMed ID: 24644297 [Abstract] [Full Text] [Related]
6. In vitro-to-in vivo prediction of P-glycoprotein-based drug interactions at the human and rodent blood-brain barrier. Hsiao P, Bui T, Ho RJ, Unadkat JD. Drug Metab Dispos; 2008 Mar; 36(3):481-4. PubMed ID: 18057117 [Abstract] [Full Text] [Related]
9. Species difference in brain penetration of P-gp and BCRP substrates among monkey, dog and mouse. Kido Y, Nanchi I, Fusamae Y, Matsuzaki T, Akazawa T, Sawada H, Iwasaki M, Nishida K, Tsuchiya E, Okuda T. Drug Metab Pharmacokinet; 2022 Feb; 42():100426. PubMed ID: 34974334 [Abstract] [Full Text] [Related]
13. Use of cassette dosing approach to examine the effects of P-glycoprotein on the brain and cerebrospinal fluid concentrations in wild-type and P-glycoprotein knockout rats. Liu X, Cheong J, Ding X, Deshmukh G. Drug Metab Dispos; 2014 Apr; 42(4):482-91. PubMed ID: 24398459 [Abstract] [Full Text] [Related]
14. Influence of time to achieve substrate distribution equilibrium between brain tissue and blood on quantitation of the blood-brain barrier P-glycoprotein effect. Padowski JM, Pollack GM. Brain Res; 2011 Dec 02; 1426():1-17. PubMed ID: 22036081 [Abstract] [Full Text] [Related]
15. Investigation of utility of cerebrospinal fluid drug concentration as a surrogate for interstitial fluid concentration using microdialysis coupled with cisternal cerebrospinal fluid sampling in wild-type and Mdr1a(-/-) rats. Nagaya Y, Nozaki Y, Takenaka O, Watari R, Kusano K, Yoshimura T, Kusuhara H. Drug Metab Pharmacokinet; 2016 Feb 02; 31(1):57-66. PubMed ID: 26830080 [Abstract] [Full Text] [Related]
18. Inhibition of P-glycoprotein activity at the primate blood-brain barrier increases the distribution of nelfinavir into the brain but not into the cerebrospinal fluid. Kaddoumi A, Choi SU, Kinman L, Whittington D, Tsai CC, Ho RJ, Anderson BD, Unadkat JD. Drug Metab Dispos; 2007 Sep 02; 35(9):1459-62. PubMed ID: 17591677 [Abstract] [Full Text] [Related]